Heterogeneity derived from <SUP>18</SUP>F-FDG PET/CT predicts immunotherapy outcome for metastatic triple-negative breast cancer patients

Yizhao Xie,Cheng Liu,Yannan Zhao,Chengcheng Gong,Yi Li,Shihui Hu,Shaoli Song,Xichun Hu,Zhongyi Yang,Biyun Wang

DOI: https://doi.org/10.1002/cam4.4522

IF: 4.711

2022-01-01

Cancer Medicine

Abstract:Background Recently, immunotherapy has been used to treat metastatic triple-negative breast cancer (mTNBC). Basic research has indicated a relation between tumor heterogeneity and the immune response. Tumor heterogeneity derived from F-18-FDG PET/CT is a potential predictor of chemotherapy results; however, few studies have focused on immunotherapy. This study aims to develop a convenient and efficient measurement of tumor heterogeneity for the prediction of immunotherapy in mTNBC patients. Methods We enrolled mTNBC patients who received immunotherapy (PD-1/PD-L1 antibody) plus chemotherapy as first-line treatment and underwent F-18-FDG PET/CT scans before treatment. We defined a novel index representing tumor heterogeneity calculated from the standard uptake value (SUV) as IATH and IETH. Optimal cutoffs were determined using time-dependent receiver operator characteristics (ROC) analysis. Results A total of 32 patients were enrolled and analyzed in this trial. A significantly longer median PFS was observed in the low SUVmax group than in the high SUVmax group (9.4 vs. 5.8 months, HR = 0.3, 95% CI 0.1-0.9, p = 0.025). The median PFS of low-IATH patients was significantly longer than that of high-IATH patients (HR = 0.3, 95% CI 0.1-0.8, p = 0.022). Similarly, patients with low IETH had significantly longer PFS than patients with high IETH (9.4 vs. 4.9 months, HR = 0.3, 95% CI 0.1-0.7, p = 0.01). Multivariate analysis demonstrated IETH as an independent predictor of PFS. Conclusions This study proposed a novel method to assess intratumor and intertumor heterogeneity among metastatic breast cancer patients and determined that baseline IETH derived from F-18-FDG PET/CT could represent a simple and promising predictor for first-line immunotherapy among mTNBC patients.